Cytori Therapeutics: ROTH Conference (Cytori) - Mar 19, 2013 - "ADRCs may preserve functional capacity, improve perfusion, reduce scar, improve left ventricular contractility and lead to lower mortality"; "Safety: No malignant arrhythmias, adverse events similar in both groups"; "Harvesting ADRCs and transendocardial delivery is safe and feasible in patients with CAD"; "MVO2 & METS: Preserved function in ADRC at 6 & 18 months compared to controls (p=0.03, p=0.01)"; "Total Left Ventricular Mass (MRI): ADRC's demonstrated significant improvement over controls (p<0.001)"; "Wall Motion Score Index: ADCR's demonstrated significant improvement in wall motion score index (p<0.04) with a stabilization of scare size compared to controls"; "Inducible Ischemia (SPECT): was reduced in ADRCs patients up to 18 months (p<0.05)"; "Cardiac Mortality: At 27 months follow-up, fewer ADRC patient deaths compared to controls (1 of 21 in ADRCs vs 2 of 6 controls; p=0.10)"
P1 data • Acute Coronary Syndrome
|